Source:http://linkedlifedata.com/resource/pubmed/id/19229163
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1306
|
| pubmed:dateCreated |
2009-2-20
|
| pubmed:abstractText |
The incidence of oral cancer appears to be increasing, especially in younger patients. Risk factors include use of tobacco and alcohol, and exposure to human papillomavirus. ViziLite Plus (Zila Pharmaceuticals) is a combination device that uses fluorescent light and toluidine blue tissue staining to help dentists identify abnormal changes in the mucous membranes of the oral cavity. Originally developed for detecting abnormal growths on the uterine cervix, in 2001 it received FDA clearance for "identification, evaluation, and monitoring of oral mucosal abnormalities in a patient population at increased risk for oral cancer." The toluidine blue marking system was cleared for inclusion in 2005.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1523-2859
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
23
|
| pubmed:volume |
51
|
| pubmed:owner |
NLM
|
| pubmed:pagination |
15-6
|
| pubmed:meshHeading | |
| pubmed:year |
2009
|
| pubmed:articleTitle |
Screening for oral cancer.
|
| pubmed:publicationType |
Journal Article
|